143 related articles for article (PubMed ID: 11529866)
21. Chemotherapy stimulates syndecan-1 shedding: a potentially negative effect of treatment that may promote tumor relapse.
Ramani VC; Sanderson RD
Matrix Biol; 2014 Apr; 35():215-22. PubMed ID: 24145151
[TBL] [Abstract][Full Text] [Related]
22. Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation.
Dhodapkar MV; Abe E; Theus A; Lacy M; Langford JK; Barlogie B; Sanderson RD
Blood; 1998 Apr; 91(8):2679-88. PubMed ID: 9531576
[TBL] [Abstract][Full Text] [Related]
23. Soluble syndecan-1 promotes growth of myeloma tumors in vivo.
Yang Y; Yaccoby S; Liu W; Langford JK; Pumphrey CY; Theus A; Epstein J; Sanderson RD
Blood; 2002 Jul; 100(2):610-7. PubMed ID: 12091355
[TBL] [Abstract][Full Text] [Related]
24. Syndecan-1 in multiple myeloma: relationship to conventional prognostic factors.
Aref S; Goda T; El-Sherbiny M
Hematology; 2003 Aug; 8(4):221-8. PubMed ID: 12911939
[TBL] [Abstract][Full Text] [Related]
25. Protein kinase C regulates the recruitment of syndecan-4 into focal contacts.
Baciu PC; Goetinck PF
Mol Biol Cell; 1995 Nov; 6(11):1503-13. PubMed ID: 8589452
[TBL] [Abstract][Full Text] [Related]
26. Insulin promotes shedding of syndecan ectodomains from 3T3-L1 adipocytes: a proposed mechanism for stabilization of extracellular lipoprotein lipase.
Reizes O; Goldberger O; Smith AC; Xu Z; Bernfield M; Bickel PE
Biochemistry; 2006 May; 45(18):5703-11. PubMed ID: 16669614
[TBL] [Abstract][Full Text] [Related]
27. Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis.
Frassanito MA; Cusmai A; Iodice G; Dammacco F
Blood; 2001 Jan; 97(2):483-9. PubMed ID: 11154226
[TBL] [Abstract][Full Text] [Related]
28. Syndecan-1 (CD 138) in myeloma and lymphoid malignancies: a multifunctional regulator of cell behavior within the tumor microenvironment.
Dhodapkar MV; Sanderson RD
Leuk Lymphoma; 1999 Jun; 34(1-2):35-43. PubMed ID: 10350330
[TBL] [Abstract][Full Text] [Related]
29. Characterization of anti-CD138 monoclonal antibodies as tools for investigating the molecular polymorphism of syndecan-1 in human lymphoma cells.
Gattei V; Godeas C; Degan M; Rossi FM; Aldinucci D; Pinto A
Br J Haematol; 1999 Jan; 104(1):152-62. PubMed ID: 10027728
[TBL] [Abstract][Full Text] [Related]
30. Plasmin- and thrombin-accelerated shedding of syndecan-4 ectodomain generates cleavage sites at Lys(114)-Arg(115) and Lys(129)-Val(130) bonds.
Schmidt A; Echtermeyer F; Alozie A; Brands K; Buddecke E
J Biol Chem; 2005 Oct; 280(41):34441-6. PubMed ID: 16087677
[TBL] [Abstract][Full Text] [Related]
31. Heparan sulfate proteoglycan expression in chronic cholestatic human liver diseases.
Roskams T; Rosenbaum J; De Vos R; David G; Desmet V
Hepatology; 1996 Sep; 24(3):524-32. PubMed ID: 8781318
[TBL] [Abstract][Full Text] [Related]
32. Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma.
Tai YT; Li X; Tong X; Santos D; Otsuki T; Catley L; Tournilhac O; Podar K; Hideshima T; Schlossman R; Richardson P; Munshi NC; Luqman M; Anderson KC
Cancer Res; 2005 Jul; 65(13):5898-906. PubMed ID: 15994968
[TBL] [Abstract][Full Text] [Related]
33. Expression of syndecans, a heparan sulfate proteoglycan, in malignant gliomas: participation of nuclear factor-kappaB in upregulation of syndecan-1 expression.
Watanabe A; Mabuchi T; Satoh E; Furuya K; Zhang L; Maeda S; Naganuma H
J Neurooncol; 2006 Mar; 77(1):25-32. PubMed ID: 16132527
[TBL] [Abstract][Full Text] [Related]
34. Modulation of phorbol ester-induced regulation of matrix metalloproteinases and tissue inhibitors of metalloproteinases by SB203580, a specific inhibitor of p38 mitogen-activated protein kinase.
Park MJ; Park IC; Hur JH; Kim MS; Lee HC; Woo SH; Lee KH; Rhee CH; Hong SI; Lee SH
J Neurosurg; 2002 Jul; 97(1):112-8. PubMed ID: 12134900
[TBL] [Abstract][Full Text] [Related]
35. Syndecan-1 expression is decreased with increasing aggressiveness of basal cell carcinoma.
Bayer-Garner IB; Dilday B; Sanderson RD; Smoller BR
Am J Dermatopathol; 2000 Apr; 22(2):119-22. PubMed ID: 10770430
[TBL] [Abstract][Full Text] [Related]
36. Protein kinase C delta and eta isoenzymes control the shedding of the interleukin 6 receptor alpha in myeloma cells.
Thabard W; Collette M; Bataille R; Amiot M
Biochem J; 2001 Aug; 358(Pt 1):193-200. PubMed ID: 11485567
[TBL] [Abstract][Full Text] [Related]
37. Syndecan-1 expression on malignant cells from the blood and marrow of patients with plasma cell proliferative disorders and B-cell chronic lymphocytic leukemia.
Witzig TE; Kimlinger T; Stenson M; Therneau T
Leuk Lymphoma; 1998 Sep; 31(1-2):167-75. PubMed ID: 9720726
[TBL] [Abstract][Full Text] [Related]
38. Synergistic effect of tumor necrosis factor-alpha and interferon-gamma on enterocyte shedding of syndecan-1 and associated decreases in internalization of Listeria monocytogenes and Staphylococcus aureus.
Henry-Stanley MJ; Zhang B; Erlandsen SL; Wells CL
Cytokine; 2006 Jun; 34(5-6):252-9. PubMed ID: 16884912
[TBL] [Abstract][Full Text] [Related]
39. RANTES (CCL5) induces a CCR5-dependent accelerated shedding of syndecan-1 (CD138) and syndecan-4 from HeLa cells and forms complexes with the shed ectodomains of these proteoglycans as well as with those of CD44.
Charnaux N; Brule S; Chaigneau T; Saffar L; Sutton A; Hamon M; Prost C; Lievre N; Vita C; Gattegno L
Glycobiology; 2005 Feb; 15(2):119-30. PubMed ID: 15355933
[TBL] [Abstract][Full Text] [Related]
40. Expression of glypican-1, syndecan-1 and syndecan-4 mRNAs protein kinase C-regulated in rat immature Sertoli cells by semi-quantitative RT-PCR analysis.
Brucato S; Harduin-Lepers A; Godard F; Bocquet J; Villers C
Biochim Biophys Acta; 2000 Mar; 1474(1):31-40. PubMed ID: 10699487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
